An article published in the Journal of Rheumatology has concluded that in those people who have achieved remission in ankylosing spondylitis through use of a TNF-a Inhibitor, it is possible to lower the frequency of treatments and the medication will stay effective.
The TNF-a Inhibitors, or biologic medications, have been shown effective in treating ankylosing spondylitis and the inflammation caused by the disease. Four of these medications now have FDA approval in the United States for treating AS: Enbrel, Humira, Remicade and Simponi. For more information on AS medications, click here.
This study examined dosage adjustments in three: Enbrel, Humira and Remicade.
The authors of the study state that, "Remission had occurred in 35% of the patients with AS under anti-TNF-a inhibitor therapy. Dosage adjustment and progressively reducing treatment frequency was effective in maintaining remission."
To read the study abstract, click here.
Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!